ADC Therapeutics SA
NYSE:ADCT
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
ROE Comparison
ADC Therapeutics SA Competitors
Country | CH |
Market Cap | 371.4m USD |
ROE |
806%
|
Country | US |
Market Cap | 319.7B USD |
ROE |
35%
|
Country | US |
Market Cap | 153.2B USD |
ROE |
136%
|
Country | US |
Market Cap | 108.4B USD |
ROE |
23%
|
Country | US |
Market Cap | 105.1B USD |
ROE |
16%
|
Country | US |
Market Cap | 91.4B USD |
ROE |
26%
|
Country | AU |
Market Cap | 139.1B AUD |
ROE |
15%
|
Country | US |
Market Cap | 43.1B USD |
ROE |
-28%
|
Country | US |
Market Cap | 41.6B USD |
ROE |
-29%
|
Country | US |
Market Cap | 31.2B USD |
ROE |
8%
|
Country | KR |
Market Cap | 40.1T KRW |
ROE |
14%
|
ROE Distribution
ROE Distribution
Biotechnology Industry
Profitability Report
View the profitability report to see the full profitability analysis for ADC Therapeutics SA.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on ADC Therapeutics SA's most recent financial statements, the company has ROE of 806.2%.